COMMUNIQUÉS West-GlobeNewswire

Digirad Corporation to Release 2017 Fourth Quarter and Year-End Financial Results on February 23, 2018
13/02/2018
SUWANEE, Ga., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ: DRAD ) will release financial results for its fourth quarter and year ended December 31, 2017, before the market opens on Friday, February 23 [...]
CV Sciences, Inc. to Present and Exhibit as Silver Sponsor at Natural Products Expo West 2018 in Anaheim, California, March 7-11, 2018
13/02/2018
LAS VEGAS, Feb. 13, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI), preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, announced today that its industry dominating [...]
Sanofi : Information concerning the total number of voting rights and shares
13/02/2018
Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/1cb41595-1a62-4ba3-8cef-ecfd855d267e
Sanofi : Informations relatives au nombre total de droits de vote et d'actions
13/02/2018
Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/92a363dc-7bd0-4339-a43f-78bc215823f3
Cytovance® Biologics, Inc. announces completion of first batch in new state-of-the-art 1000L microbial facility
13/02/2018
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces completion of first batch in [...]
Trading by management and of close relations to management
13/02/2018
Please see attached for details of the transaction http://prlibrary-eu.nasdaq.com/Resource/Download/79c8b9e6-f1b0-45d0-827b-e8b1dcb5773f
Transactions in relation to share buyback program
13/02/2018
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Affimed Announces Pricing of Public Offering of Common Stock
13/02/2018
Heidelberg, Germany February 13, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the pricing [...]
Olainfarm to Strengthen Belarus Operations
13/02/2018
Olaine, 2018-02-13 09:00 CET (GLOBE NEWSWIRE) -- “Since acquisition of daughter companies we are putting a lot of effort to integrate them and use as many synergies as we can. In NPK Biotest, we have created a certified [...]
Verona Pharma Provides Clinical Development Update
13/02/2018
LONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA ) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
13/02/2018
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France - February 13, 2018 - [...]
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
13/02/2018
Glatopa ® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone ®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa ® 20 mg/mL, which was launched in the US in June 2015, [...]
Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL
13/02/2018
--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE ® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of multiple sclerosis (MS [...]
Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
13/02/2018
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus Final Trial Results Expected in [...]
Néovacs annonce les conclusions positives de la dernière revue des données pour l'étude clinique de phase IIb avec l'IFNalpha Kinoïde dans le lupus par l'iDSMB
13/02/2018
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE Néovacs annonce les conclusions positives de la dernière revue des données pour l'étude clinique de phase IIb avec l'IFNalpha Kinoïde dans le lupus par [...]
Orkla Food Ingredients Expands its Acrylamide-Reducing Yeast Technology Licence Agreement with Renaissance BioScience Corp.
13/02/2018
OSLO, Norway and VANCOUVER, British Columbia, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Orkla Food Ingredients, a business area of Orkla ASA (OSE: ORK ), and Renaissance BioScience Corp. have agreed to expand their licence [...]
Gallup and Sharecare Release 2017 State Well-Being Rankings
13/02/2018
WASHINGTON and ATLANTA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- World-leading analytics and advice firm Gallup, and Sharecare, the digital health company helping people manage all their health in one place, today announced [...]
Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
13/02/2018
SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a clinical-stage, women’s biopharmaceutical company, today announced that it intends to offer primary shares of its common stock and [...]
MediciNova Announces Closing of Underwritten Public Offering of Common Stock
13/02/2018
LA JOLLA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Pages